AbbVie (ABBV) Beats Estimates as Sales of Humira Continues Climb
7/26/2013 7:15:42 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
AbbVie Inc. (ABBV), the drugmaker carved out of Abbott (ABT) Laboratories at the start of the year, reported profit that beat analyst estimates and raised its 2013 forecast after sales of top medicine Humira gained on price increases and new indications. Earnings, excluding one-time items, of 82 cents a share topped by 3 cents the average of 10 analysts’ estimates compiled by Bloomberg. Full-year profit is expected to be $3.07 to $3.13 a share, the Abbott Park, Illinois-based company said in a statement today. Its previous outlook was for profit of at least $3.03 a share.
Help employers find you! Check out all the jobs and post your resume.
comments powered by